Phase i studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers

Jorge Cortes, Kenji Tamura, Daniel J. Deangelo, Johann De Bono, David Lorente, Mark Minden, Geoffrey L. Uy, Hagop Kantarjian, Lisa S. Chen, Varsha Gandhi, Robert Godin, Karen Keating, Kristen McEachern, Karthick Vishwanathan, Janet Elizabeth Pease, Emma Dean

Research output: Contribution to journalArticle

Abstract

Background: Proviral integration Moloney virus (PIM) kinases (PIM1, 2 and 3) are overexpressed in several tumour types and contribute to oncogenesis. AZD1208 is a potent ATP-competitive PIM kinase inhibitor investigated in patients with recurrent or refractory acute myeloid leukaemia (AML) or advanced solid tumours. Methods: Two dose-escalation studies were performed to evaluate the safety and tolerability, and to define the maximum tolerated dose (MTD), of AZD1208 in AML and solid tumours. Secondary objectives were to evaluate the pharmacokinetics, pharmacodynamics (PD) and preliminary efficacy of AZD1208. Results: Sixty-seven patients received treatment: 32 in the AML study over a 120-900 mg dose range, and 25 in the solid tumour study over a 120-800 mg dose range. Nearly all patients (98.5%) in both studies experienced adverse events, mostly gastrointestinal (92.5%). Dose-limiting toxicities included rash, fatigue and vomiting. AZD1208 was not tolerated at 900 mg, and the protocol-defined MTD was not confirmed. AZD1208 increased CYP3A4 activity after multiple dosing, resulting in increased drug clearance. There were no clinical responses; PD analysis showed biological activity of AZD1208. Conclusions: Despite the lack of single-agent clinical efficacy with AZD1208, PIM kinase inhibition may hold potential as an anticancer treatment, perhaps in combination with other agents.

Original languageEnglish (US)
Pages (from-to)1425-1433
Number of pages9
JournalBritish Journal of Cancer
Volume118
Issue number11
DOIs
StatePublished - May 1 2018
Externally publishedYes

Fingerprint

Virus Integration
Phosphotransferases
Neoplasms
Acute Myeloid Leukemia
Maximum Tolerated Dose
Cytochrome P-450 CYP3A
AZD1208
Exanthema
Vomiting
Fatigue
Carcinogenesis
Pharmacokinetics
Adenosine Triphosphate
Safety
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase i studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. / Cortes, Jorge; Tamura, Kenji; Deangelo, Daniel J.; De Bono, Johann; Lorente, David; Minden, Mark; Uy, Geoffrey L.; Kantarjian, Hagop; Chen, Lisa S.; Gandhi, Varsha; Godin, Robert; Keating, Karen; McEachern, Kristen; Vishwanathan, Karthick; Pease, Janet Elizabeth; Dean, Emma.

In: British Journal of Cancer, Vol. 118, No. 11, 01.05.2018, p. 1425-1433.

Research output: Contribution to journalArticle

Cortes, J, Tamura, K, Deangelo, DJ, De Bono, J, Lorente, D, Minden, M, Uy, GL, Kantarjian, H, Chen, LS, Gandhi, V, Godin, R, Keating, K, McEachern, K, Vishwanathan, K, Pease, JE & Dean, E 2018, 'Phase i studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers', British Journal of Cancer, vol. 118, no. 11, pp. 1425-1433. https://doi.org/10.1038/s41416-018-0082-1
Cortes, Jorge ; Tamura, Kenji ; Deangelo, Daniel J. ; De Bono, Johann ; Lorente, David ; Minden, Mark ; Uy, Geoffrey L. ; Kantarjian, Hagop ; Chen, Lisa S. ; Gandhi, Varsha ; Godin, Robert ; Keating, Karen ; McEachern, Kristen ; Vishwanathan, Karthick ; Pease, Janet Elizabeth ; Dean, Emma. / Phase i studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. In: British Journal of Cancer. 2018 ; Vol. 118, No. 11. pp. 1425-1433.
@article{2d247080ec494ad7be2f6b5784d18bc2,
title = "Phase i studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers",
abstract = "Background: Proviral integration Moloney virus (PIM) kinases (PIM1, 2 and 3) are overexpressed in several tumour types and contribute to oncogenesis. AZD1208 is a potent ATP-competitive PIM kinase inhibitor investigated in patients with recurrent or refractory acute myeloid leukaemia (AML) or advanced solid tumours. Methods: Two dose-escalation studies were performed to evaluate the safety and tolerability, and to define the maximum tolerated dose (MTD), of AZD1208 in AML and solid tumours. Secondary objectives were to evaluate the pharmacokinetics, pharmacodynamics (PD) and preliminary efficacy of AZD1208. Results: Sixty-seven patients received treatment: 32 in the AML study over a 120-900 mg dose range, and 25 in the solid tumour study over a 120-800 mg dose range. Nearly all patients (98.5{\%}) in both studies experienced adverse events, mostly gastrointestinal (92.5{\%}). Dose-limiting toxicities included rash, fatigue and vomiting. AZD1208 was not tolerated at 900 mg, and the protocol-defined MTD was not confirmed. AZD1208 increased CYP3A4 activity after multiple dosing, resulting in increased drug clearance. There were no clinical responses; PD analysis showed biological activity of AZD1208. Conclusions: Despite the lack of single-agent clinical efficacy with AZD1208, PIM kinase inhibition may hold potential as an anticancer treatment, perhaps in combination with other agents.",
author = "Jorge Cortes and Kenji Tamura and Deangelo, {Daniel J.} and {De Bono}, Johann and David Lorente and Mark Minden and Uy, {Geoffrey L.} and Hagop Kantarjian and Chen, {Lisa S.} and Varsha Gandhi and Robert Godin and Karen Keating and Kristen McEachern and Karthick Vishwanathan and Pease, {Janet Elizabeth} and Emma Dean",
year = "2018",
month = "5",
day = "1",
doi = "10.1038/s41416-018-0082-1",
language = "English (US)",
volume = "118",
pages = "1425--1433",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Phase i studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers

AU - Cortes, Jorge

AU - Tamura, Kenji

AU - Deangelo, Daniel J.

AU - De Bono, Johann

AU - Lorente, David

AU - Minden, Mark

AU - Uy, Geoffrey L.

AU - Kantarjian, Hagop

AU - Chen, Lisa S.

AU - Gandhi, Varsha

AU - Godin, Robert

AU - Keating, Karen

AU - McEachern, Kristen

AU - Vishwanathan, Karthick

AU - Pease, Janet Elizabeth

AU - Dean, Emma

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Background: Proviral integration Moloney virus (PIM) kinases (PIM1, 2 and 3) are overexpressed in several tumour types and contribute to oncogenesis. AZD1208 is a potent ATP-competitive PIM kinase inhibitor investigated in patients with recurrent or refractory acute myeloid leukaemia (AML) or advanced solid tumours. Methods: Two dose-escalation studies were performed to evaluate the safety and tolerability, and to define the maximum tolerated dose (MTD), of AZD1208 in AML and solid tumours. Secondary objectives were to evaluate the pharmacokinetics, pharmacodynamics (PD) and preliminary efficacy of AZD1208. Results: Sixty-seven patients received treatment: 32 in the AML study over a 120-900 mg dose range, and 25 in the solid tumour study over a 120-800 mg dose range. Nearly all patients (98.5%) in both studies experienced adverse events, mostly gastrointestinal (92.5%). Dose-limiting toxicities included rash, fatigue and vomiting. AZD1208 was not tolerated at 900 mg, and the protocol-defined MTD was not confirmed. AZD1208 increased CYP3A4 activity after multiple dosing, resulting in increased drug clearance. There were no clinical responses; PD analysis showed biological activity of AZD1208. Conclusions: Despite the lack of single-agent clinical efficacy with AZD1208, PIM kinase inhibition may hold potential as an anticancer treatment, perhaps in combination with other agents.

AB - Background: Proviral integration Moloney virus (PIM) kinases (PIM1, 2 and 3) are overexpressed in several tumour types and contribute to oncogenesis. AZD1208 is a potent ATP-competitive PIM kinase inhibitor investigated in patients with recurrent or refractory acute myeloid leukaemia (AML) or advanced solid tumours. Methods: Two dose-escalation studies were performed to evaluate the safety and tolerability, and to define the maximum tolerated dose (MTD), of AZD1208 in AML and solid tumours. Secondary objectives were to evaluate the pharmacokinetics, pharmacodynamics (PD) and preliminary efficacy of AZD1208. Results: Sixty-seven patients received treatment: 32 in the AML study over a 120-900 mg dose range, and 25 in the solid tumour study over a 120-800 mg dose range. Nearly all patients (98.5%) in both studies experienced adverse events, mostly gastrointestinal (92.5%). Dose-limiting toxicities included rash, fatigue and vomiting. AZD1208 was not tolerated at 900 mg, and the protocol-defined MTD was not confirmed. AZD1208 increased CYP3A4 activity after multiple dosing, resulting in increased drug clearance. There were no clinical responses; PD analysis showed biological activity of AZD1208. Conclusions: Despite the lack of single-agent clinical efficacy with AZD1208, PIM kinase inhibition may hold potential as an anticancer treatment, perhaps in combination with other agents.

UR - http://www.scopus.com/inward/record.url?scp=85046889218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046889218&partnerID=8YFLogxK

U2 - 10.1038/s41416-018-0082-1

DO - 10.1038/s41416-018-0082-1

M3 - Article

C2 - 29765150

AN - SCOPUS:85046889218

VL - 118

SP - 1425

EP - 1433

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 11

ER -